12:00 AM
 | 
Mar 23, 2015
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
CompanyBankAnalystCoverageOpinionWk chg3/20 cls
Actelion Ltd. (SIX:ATLN)UBSGuillaume van RenterghemDowngradeNeutral (from buy)4%CHF 118.90
van Renterghem downgraded after Uptravi selexipag "failed to show a mortality benefit as secondary endpoint" in the Phase III GRIPHON trial to treat pulmonary arterial hypertension (PAH). He also noted that the long-acting prostacyclin (IP) receptor (PGI2; PTGIR) agonist has a similar safety profile to other prostacyclins, which he believes makes it a third-line...

Read the full 425 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >